ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,361Medicare Part D Prescriptions Filled, Including Refills

Rank: 28 out of 546

$684K Total Retail Price of All Prescriptions

Rank: 25 out of 546

301 Patients Receiving at Least One Drug in Part D
35%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

39% of this provider’s 301 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

21% of this provider’s 301 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 3,203 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
OXYCODONE HCL 590 61 S2 1 15
HYDROCODONE-ACETAMINOPHEN 579 143 S3 2 8
LISINOPRIL 339 96 3 1
SIMVASTATIN 322 142 4 2
LEVOTHYROXINE SODIUM 299 101 5 3
OMEPRAZOLE 298 113 6 4
METHADONE HCL 273 11 S2 7 61
METFORMIN HCL 230 46 8 10
OXYCODONE-ACETAMINOPHEN 215 49 S2 9 54
CYCLOBENZAPRINE HCL 193 27 R 10 34
FUROSEMIDE 171 74 11 5
METOPROLOL TARTRATE 166 70 12 6
RANITIDINE HCL 155 15 13 23
ENALAPRIL MALEATE 152 52 14 59
PANTOPRAZOLE SODIUM 149 21 15 18
ATENOLOL 149 65 15 12
AMLODIPINE BESYLATE 148 65 17 9
HYDROCHLOROTHIAZIDE 142 70 18 7
ATORVASTATIN CALCIUM 139 73 19 11
METOPROLOL SUCCINATE 132 39 20 17
IBUPROFEN 110 15 21 70
PROAIR HFA 107 24 22 27
ISOSORBIDE MONONITRATE ER 106 46 23 32
ACTOS 102 42 24 129
GABAPENTIN 102 49 24 16
MORPHINE SULFATE ER 101 0 S2 26 67
FENOFIBRATE 100 24 27 87
NEXIUM 99 18 28 52
POTASSIUM CHLORIDE 98 39 29 30
COMBIVENT 85 35 30 71
ZOLPIDEM TARTRATE 85 14 30 26
ROPINIROLE HCL 84 0 32 64
GLYBURIDE 84 25 R 32 45
LYRICA 82 0 34 69
ADVAIR DISKUS 79 39 35 20
SPIRIVA 78 23 36 28
MORPHINE SULFATE 78 0 S2 36 138
SERTRALINE HCL 75 24 38 14
KADIAN 70 0 S2 39 219
DOXAZOSIN MESYLATE 67 21 40 98
TRAMADOL HCL 65 17 41 19
FLUTICASONE PROPIONATE 63 22 42 42
LIPITOR 63 43 42 80
BACLOFEN 63 12 42 86
WARFARIN SODIUM 62 31 45 13
CRESTOR 60 0 46 36
AMITRIPTYLINE HCL 60 0 R 46 48
ALENDRONATE SODIUM 56 26 48 38
CLONIDINE HCL 54 0 49 115
SUBOXONE 51 0 50 40
OXYCONTIN 51 0 S2 50 75
PAROXETINE HCL 51 17 50 43
CITALOPRAM HBR 50 15 53 21
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.